APA (7th ed.) Citation

Wei, Q., Tan, Y., Xu, P., Tao, E., Lu, Z., Pan, X., . . . Zhou, J. (2022). The XINDI Study: A Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Safinamide as Add-On Therapy to Levodopa in Chinese Patients with Parkinson's Disease with Motor Fluctuations. CNS Drugs, 36(11), 1217. https://doi.org/10.1007/s40263-022-00958-6

Chicago Style (17th ed.) Citation

Wei, Qianqian, et al. "The XINDI Study: A Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Safinamide as Add-On Therapy to Levodopa in Chinese Patients with Parkinson's Disease with Motor Fluctuations." CNS Drugs 36, no. 11 (2022): 1217. https://doi.org/10.1007/s40263-022-00958-6.

MLA (9th ed.) Citation

Wei, Qianqian, et al. "The XINDI Study: A Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Safinamide as Add-On Therapy to Levodopa in Chinese Patients with Parkinson's Disease with Motor Fluctuations." CNS Drugs, vol. 36, no. 11, 2022, p. 1217, https://doi.org/10.1007/s40263-022-00958-6.